Alpha Tau Medical Ltd ( (DRTS) ) just unveiled an announcement.
On February 27, 2025, Alpha Tau Medical Ltd. announced its participation in several investor conferences in March 2025, where CFO Raphi Levy will present the company’s innovative cancer therapy technology, Alpha DaRT. This participation could enhance Alpha Tau’s visibility and engagement with potential investors, potentially impacting its market positioning and stakeholder interest.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., founded in 2016, is an Israeli oncology therapeutics company that specializes in the research, development, and potential commercialization of the Alpha DaRT technology for treating solid tumors. The technology, initially developed by professors from Tel Aviv University, focuses on delivering highly potent alpha-irradiation directly to tumors while sparing surrounding healthy tissue.
YTD Price Performance: -12.90%
Average Trading Volume: 90,323
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $188.8M
For an in-depth examination of DRTS stock, go to TipRanks’ Stock Analysis page.